TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Impact · against what's priced in

TuHURA Biosciences (HURA) gains structural value through the issuance of a U.S. patent securing a monopoly on its DOR technology through 2043, notably extending the application to cellular therapies. While preclinical progress in AML and MDS is noted, the immediate value driver is the intellectual property protection rather than clinical data.

HURA+0.60: No priced-in read yet

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

What matters in this story

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

What matters in this story

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

How each ticker is affected

Connected tickers

Track these names every morning.

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

What matters in this story

Next reads from the same story arc

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

What matters in this story

Next reads from the same story arc

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

How each ticker is affected

Connected tickers

Track these names every morning.

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval